#EXP00149

General

Accession EXP00149
Activity Formation (3-24h)
Date 2013-11-26
Administration In solution
Model in vitro
Organism Staphylococcus aureus
Status Validated
Notes Sa7 clinical isolate

Peptide

BMAP-28

GGLRSLGRKILRAWKKYGPIIVPIIRI

Experimental activity

Method Concentration Notes
Crystal violet assay 2.603 uM No notes
Crystal violet assay 1.302 uM No notes
Crystal violet assay 0.651 uM No notes

References

Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients

A. Pompilio, M. Scocchi, S. Pomponio, F. Guida, A. Di Primio, E. Fiscarelli, R. Gennaro, G. Di Bonaventura

2011. Peptides 9:1807-1814